These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25433369)

  • 1. Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.
    Liao MF; Chang KH; Lyu RK; Huang CC; Chang HS; Wu YR; Chen CM; Chu CC; Kuo HC; Ro LS
    BMC Neurol; 2014 Nov; 14():218. PubMed ID: 25433369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
    Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Hyun JW; Huh SY; Shin HJ; Woodhall M; Kim SH; Irani SR; Lee SH; Waters P; Kim HJ
    Mult Scler; 2019 Apr; 25(4):585-590. PubMed ID: 29512413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain lesion distribution criteria distinguish demyelinating diseases in China.
    Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
    Matthews L; Marasco R; Jenkinson M; Küker W; Luppe S; Leite MI; Giorgio A; De Stefano N; Robertson N; Johansen-Berg H; Evangelou N; Palace J
    Neurology; 2013 Apr; 80(14):1330-7. PubMed ID: 23486868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
    Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients.
    Carnero Contentti E; Marques VD; Soto de Castillo I; Tkachuk V; Barreira AA; Caride A; Castillo MC; Cristiano E; de Aquino Cruz C; Braga Diégues Serva G; Santos ACD; Labarca R; Lavigne Moreira C; López PA; Miguez J; Molina O; Pettinicchi JP; Rojas JI
    Mult Scler; 2020 Jul; 26(8):945-954. PubMed ID: 31124748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging in neuromyelitis optica spectrum disorder.
    Clarke L; Arnett S; Lilley K; Liao J; Bhuta S; Broadley SA
    Clin Exp Immunol; 2021 Dec; 206(3):251-265. PubMed ID: 34080180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status.
    Matsushita T; Isobe N; Piao H; Matsuoka T; Ishizu T; Doi H; Masaki K; Yoshiura T; Yamasaki R; Ohyagi Y; Kira J
    J Neurol Sci; 2010 Apr; 291(1-2):37-43. PubMed ID: 20122699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
    Carnero Contentti E; Rojas JI; Criniti J; Lopez PA; Daccach Marques V; Soto de Castillo I; Tkachuk V; Marrodan M; Correale J; Farez MF; Kim HJ; Hyun JW; Messina S; Mariano R; Rocca MA; Cacciaguerra L; Filippi M; Palace J; Juryńczyk M
    Mult Scler Relat Disord; 2022 May; 61():103778. PubMed ID: 35452969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
    Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
    Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease?
    Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP
    Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Masuda H; Mori M; Hirano S; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):32-40. PubMed ID: 34362853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating multiple sclerosis and neuromyelitis optica spectrum disorders through pontine trigeminal nerve lesions: A comparative MRI study.
    Kojita Y; Kono AK; Yamada T; Yamada M; Im SW; Kozuka T; Kaida H; Kuwahara M; Nagai Y; Ishii K
    Eur J Radiol; 2024 Sep; 178():111597. PubMed ID: 38996736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.